GW&K Investment Management LLC Buys New Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

GW&K Investment Management LLC bought a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,226,758 shares of the medical device company's stock, valued at approximately $36,288,000. GW&K Investment Management LLC owned about 1.88% of Tandem Diabetes Care as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of TNDM. Trexquant Investment LP raised its position in shares of Tandem Diabetes Care by 159.9% in the 4th quarter. Trexquant Investment LP now owns 161,954 shares of the medical device company's stock worth $4,791,000 after acquiring an additional 99,631 shares in the last quarter. Quadrant Capital Group LLC grew its stake in Tandem Diabetes Care by 387.9% during the fourth quarter. Quadrant Capital Group LLC now owns 3,976 shares of the medical device company's stock worth $118,000 after purchasing an additional 3,161 shares during the period. Janney Montgomery Scott LLC lifted its stake in Tandem Diabetes Care by 55.5% in the fourth quarter. Janney Montgomery Scott LLC now owns 33,013 shares of the medical device company's stock valued at $977,000 after buying an additional 11,789 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Tandem Diabetes Care by 8.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 396,741 shares of the medical device company's stock worth $11,736,000 after buying an additional 29,730 shares in the last quarter. Finally, Lisanti Capital Growth LLC acquired a new stake in shares of Tandem Diabetes Care during the 4th quarter worth approximately $3,132,000.

Analyst Upgrades and Downgrades

TNDM has been the subject of a number of research reports. Leerink Partnrs upgraded shares of Tandem Diabetes Care from a "market perform" rating to an "outperform" rating in a report on Thursday, April 25th. Piper Sandler reiterated an "overweight" rating and issued a $50.00 price target (up previously from $35.00) on shares of Tandem Diabetes Care in a report on Friday, May 3rd. Barclays raised their price objective on Tandem Diabetes Care from $39.00 to $55.00 and gave the company an "overweight" rating in a research note on Monday, May 6th. Robert W. Baird lifted their price target on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the company a "neutral" rating in a research report on Friday, May 3rd. Finally, Wells Fargo & Company upgraded shares of Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $21.00 to $45.00 in a report on Monday, April 29th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

Tandem Diabetes Care Stock Up 4.4 %

Shares of TNDM traded up $2.09 during trading hours on Tuesday, reaching $49.32. 4,898,555 shares of the stock traded hands, compared to its average volume of 1,762,466. Tandem Diabetes Care, Inc. has a 52 week low of $13.82 and a 52 week high of $52.51. The company has a market cap of $3.19 billion, a price-to-earnings ratio of -22.73 and a beta of 1.10. The stock has a fifty day simple moving average of $36.33 and a 200 day simple moving average of $28.50. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. On average, equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.7 EPS for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.